Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Dr. Anderson offers insight into ASH's policy statements during this politically contentious time.
In his first President's Column, Dr. Kenneth Anderson speaks about ASH's commitment to education and to spreading awareness on important treatment advances and unprecedented scientific discoveries.
Kenneth C. Anderson, MD, highlights a recent trial about adult patients with relapsed and/or refractory Multiple Myeloma.
Lenalidomide Maintenance Therapy in Multiple MyelomaDr. Anderson has served on Celgene’s advisory board. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 366 1759 1769. McCarthy PL, Owzar
Microenvironment Induced Genomic Instability in Multiple MyelomaDr. Anderson indicated no relevant conflicts of interest. Koduru S, Wong E, Strowig T, et al. Dendritic cellmediated activation induced cytidine deaminase (AID) dependent induction of genomic instability in human myeloma. Blood. 2012 119
The Added Value of 18 F FDG PET CT in Defining Prognosis and Response in MyelomaDr. Anderson indicated no relevant conflicts of interest. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18 F FDG PET CT in
Delineating Molecular Mechanisms of Proteasome and Histone Deacetylase Inhibitor Induced Myeloma CytotoxicityDr. Anderson serves on advisory boards for Millennium and Novartis. Mannava S, Zhuang D, Nair JR et al. KLF9 is a novel transcriptional regulator of bortezomib and LBH589 induced
Combined Histone Deacetylase and Proteasome Inhibitor Therapy in MyelomaDr. Anderson indicated no relevant conflicts of interest. Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple
ASCT has been a standard of care in myeloma due to achievement of both high extent and frequency of response and to the prolonged progression-free survival compared with conventional chemotherapy. However, the availability of novel therapies, including bortezomib and lenalidomide, that have improved outcome has impacted the transplant paradigm.
Can We Treat Myeloma at Early Stages?Dr. Anderson indicated no relevant conflicts of interest. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) novel biological insights and development of early treatment strategies.
March-April 2017Volume 14, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology